10-Q: Xtant Medical Reports Q2 2026 Results Amid Revenue Decline

Xtant Medical Holdings, Inc. reported a significant decrease in revenue for the second quarter of 2026, primarily due to divestitures and the loss of license revenue, alongside a substantial operating expense write-off.

Summary

• Total revenue for the three months ended June 30, 2026, was $23.0 million, a 35% decrease from $35.4 million in the prior year period.
• For the six months ended June 30, 2026, total revenue was $43.9 million, a 36% decrease from $68.3 million in the prior year period.
• The company recorded a $5.0 million charge to operating expenses related to the exclusivity fee for the HEMOBLAST Bellows distribution agreement.
• Gross profit margin decreased to 57.9% for Q2 2026 from 68.6% in Q2 2025.
• Net loss for the three months ended June 30, 2026, was $9.4 million, compared to a net income of $3.6 million in the prior year period.
• Net loss for the six months ended June 30, 2026, was $12.5 million, compared to a net income of $3.6 million in the prior year period.
• Cash and cash equivalents decreased to $9.9 million as of June 30, 2026, from $17.1 million as of December 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant revenue declines, increased operating expenses, and a substantial write-off, despite some positive strategic developments.

Positives

• Entered into an exclusive distribution agreement for the HEMOBLAST Bellows product in the United States.
• Hired approximately 20 sales personnel to support the HEMOBLAST Bellows distribution.
• Completed the sale of Coflex/CoFix assets and international hardware business for $21.4 million, strengthening the balance sheet.
• The company believes its current cash and credit facilities are sufficient to meet anticipated cash requirements through at least August 2027.

Negatives

• Total revenue decreased by 35% for the three months ended June 30, 2026, and 36% for the six months ended June 30, 2026.
• Gross profit margin declined significantly due to reduced license revenue and production inefficiencies.
• A $5.0 million exclusivity fee for the Dilon distribution agreement was expensed due to uncertainty of recovery.
• Net loss for the quarter was $9.4 million, a reversal from a net income of $3.6 million in the prior year.
• Inventories increased to $33.3 million from $30.3 million.
• Accounts receivable increased to $19.4 million from $17.8 million.
• The company has a material weakness in internal control over financial reporting related to inventory valuation.

Risks

• Reliance on Dilon Technologies as the sole manufacturer for the HEMOBLAST Bellows product, with uncertainty regarding future supply beyond Q3 2026.
• Potential for termination of the Dilon Distribution Agreement, which could result in the loss of distribution rights and require reassignment/termination of sales personnel.
• Increased sales and marketing expenses due to the addition of 20 sales personnel for the HEMOBLAST Bellows product.
• The company's ability to successfully sell the HEMOBLAST Bellows product and integrate it with its existing portfolio.
• Risks associated with international operations for the HEMOBLAST Bellows product, including supply chain disruptions and foreign currency fluctuations.
• The company has a material weakness in internal control over financial reporting related to inventory valuation.
• The company's significant indebtedness and its ability to service its debt and comply with covenants.

Future Outlook

The company believes its current cash and credit facilities will be sufficient to meet its anticipated cash requirements through at least August 2027. However, it may require or seek additional capital before then, potentially through equity or debt financings, which could result in dilution to existing stockholders.

Management Comments

• Management recognized a $5.0 million charge to operating expenses during the second quarter of 2026 related to the Dilon exclusivity fee, citing uncertainty surrounding recovery and expectation that repayment was not probable.
• Management expects the loss of license and product revenue to continue to adversely impact revenues and other operating results, including gross margins, during the remainder of 2026 compared to 2025.
• Management is continuing to implement measures to remediate the identified material weakness in internal control over financial reporting related to inventory valuation.

Industry Context

StockSavvy.ai notes that Xtant Medical's significant revenue decline and shift towards a new distribution agreement for HEMOBLAST Bellows reflects the challenging market dynamics in the orthobiologics and spinal implant sector, where companies often rely on strategic partnerships and product diversification to navigate reimbursement changes and competitive pressures.

Comparison to Industry Standards

• The decline in gross profit margin to 57.9% (Q2 2026) from 68.6% (Q2 2025) is a concern, as many medical device companies strive to maintain or improve margins through operational efficiencies and product mix optimization. Competitors like Stryker and Zimmer Biomet often report higher gross margins, typically in the 70-80% range, though direct comparison is difficult due to differing product portfolios and business models.
• The net loss of $9.4 million in Q2 2026 contrasts with the profitability of larger, more established players in the spine and orthopedics market. Companies such as Medtronic or Johnson & Johnson's medical device segment generally report consistent profitability, highlighting Xtant's ongoing struggle to achieve sustainable earnings.
• The company's reliance on a single supplier for a key product (HEMOBLAST Bellows) is a significant risk not typically seen in larger, more diversified medical technology firms that often have multiple sourcing strategies or in-house manufacturing capabilities for critical components.

Legal Proceedings

• The company may be subject to potential liabilities under government regulations and various claims and legal actions, which are currently believed to be immaterial.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity issuances.
• Creditors may be impacted by the company's significant indebtedness and covenants in its credit agreements.
• Suppliers may be impacted by the company's reliance on Dilon for HEMOBLAST Bellows manufacturing and potential supply chain disruptions.

Next Steps

• Continue to implement measures to remediate the material weakness in internal control over financial reporting.
• Monitor supply of HEMOBLAST Bellows product from Dilon, with uncertainty beyond Q3 2026.
• Potentially seek additional capital through equity or debt financings if market conditions are favorable or if needed before August 2027.
• Continue to provide transition services to Companion Spine for a limited period.

Key Dates

Recommendation

The significant revenue decline, increased net loss, substantial operating expense write-off, and ongoing material weakness in internal controls, coupled with the uncertainty surrounding future supply of a key product and potential dilution from future capital raises, suggest a negative outlook for the stock.

Keywords

orthobiologics, spinal implants, medical technology, revenue, net loss, distribution agreement, HEMOBLAST Bellows, divestiture